[{"address1": "One Corporate Drive", "address2": "2nd Floor", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "800-466-6059", "website": "https://www.aligos.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-\u00df agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 70, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lawrence M. Blatt MBA, Ph.D.", "age": 62, "title": "CEO, President & Chairman of the Board", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 1006234, "exercisedValue": 0, "unexercisedValue": 228334}, {"maxAge": 1, "name": "Ms. Kristina  Engeseth M.B.A.", "title": "Senior VP and Head of People & Culture", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sushmita M. Chanda DABT, Ph.D.", "age": 57, "title": "Executive Vice President & Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David B. Smith Ph.D.", "title": "Executive VP & Head of Chemical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tse-I  Lin Ph.D.", "title": "Senior VP of Early Compound Development & Belgian Site Head", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 6.035, "open": 6.12, "dayLow": 5.57, "dayHigh": 6.32, "regularMarketPreviousClose": 6.035, "regularMarketOpen": 6.12, "regularMarketDayLow": 5.57, "regularMarketDayHigh": 6.32, "payoutRatio": 0.0, "beta": 2.722, "forwardPE": -0.46979865, "volume": 160241, "regularMarketVolume": 160241, "averageVolume": 188001, "averageVolume10days": 111220, "averageDailyVolume10Day": 111220, "bid": 5.47, "ask": 5.73, "bidSize": 1, "askSize": 1, "marketCap": 34240136, "fiftyTwoWeekLow": 3.76, "fiftyTwoWeekHigh": 46.8, "priceToSalesTrailing12Months": 8.679376, "fiftyDayAverage": 9.3309, "twoHundredDayAverage": 16.71975, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -14323858, "profitMargins": 0.0, "floatShares": 4373872, "sharesOutstanding": 5314310, "sharesShort": 831999, "sharesShortPriorMonth": 795342, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.1361, "heldPercentInsiders": 0.11581001, "heldPercentInstitutions": 0.342, "shortRatio": 4.58, "shortPercentOfFloat": 0.2031, "impliedSharesOutstanding": 6114310, "bookValue": -7.497, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -131211000, "trailingEps": -20.94, "forwardEps": -11.92, "lastSplitFactor": "1:25", "lastSplitDate": 1724025600, "enterpriseToRevenue": -3.631, "enterpriseToEbitda": 0.163, "52WeekChange": -0.7234568, "SandP52WeekChange": 0.09765589, "quoteType": "EQUITY", "currentPrice": 5.6, "targetHighPrice": 175.0, "targetLowPrice": 36.0, "targetMeanPrice": 85.25, "targetMedianPrice": 65.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 56939000, "totalCashPerShare": 9.312, "ebitda": -88127000, "totalDebt": 8375000, "quickRatio": 2.619, "currentRatio": 2.859, "totalRevenue": 3945000, "revenuePerShare": 0.63, "returnOnAssets": -0.50285, "returnOnEquity": -4.15837, "grossProfits": -66324000, "freeCashflow": -46987248, "operatingCashflow": -80743000, "revenueGrowth": -0.765, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -32.69157, "financialCurrency": "USD", "symbol": "ALGS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1746226240, "regularMarketTime": 1746216001, "exchange": "NCM", "messageBoardId": "finmb_581475891", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "regularMarketChangePercent": -7.207953, "regularMarketPrice": 5.6, "shortName": "Aligos Therapeutics, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1602855000000, "postMarketChangePercent": -0.148211, "postMarketPrice": 5.5917, "postMarketChange": -0.00829983, "regularMarketChange": -0.43499994, "regularMarketDayRange": "5.57 - 6.32", "fullExchangeName": "NasdaqCM", "longName": "Aligos Therapeutics, Inc.", "averageDailyVolume3Month": 188001, "fiftyTwoWeekLowChange": 1.8399999, "fiftyTwoWeekLowChangePercent": 0.48936167, "fiftyTwoWeekRange": "3.76 - 46.8", "fiftyTwoWeekHighChange": -41.2, "fiftyTwoWeekHighChangePercent": -0.8803419, "fiftyTwoWeekChangePercent": -72.34568, "earningsTimestamp": 1746534600, "earningsTimestampStart": 1746534600, "earningsTimestampEnd": 1746534600, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -20.94, "epsForward": -11.92, "epsCurrentYear": -10.7, "priceEpsCurrentYear": -0.5233645, "fiftyDayAverageChange": -3.7309003, "fiftyDayAverageChangePercent": -0.39984354, "twoHundredDayAverageChange": -11.119749, "twoHundredDayAverageChangePercent": -0.6650667, "priceToBook": -0.7469654, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-10-16", "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "displayName": "Aligos Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-05-03"}]